Abemaciclib in Breast Cancer Treatment
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
Abemaciclib in Breast Cancer Treatment
- April 26, 2017
- Reading time: 1 minute
Eli Lilly and Company announced significant findings regarding its investigational agent, Abemaciclib, for the treatment of HER2-negative advanced breast cancer. An interim analysis of the Phase 3 MONARCH 3 study demonstrated that the combination of Abemaciclib (a CDK4/6 inhibitor) with an aromatase inhibitor (CYP19 inhibitor) significantly prolonged progression-free survival (PFS) compared to aromatase inhibitor monotherapy.
The MONARCH 3 trial reached its primary endpoint of improved PFS. Additionally, the results showed improvements in objective response rates (ORR) in the combination arm. Detailed findings from this clinical trial are expected to be presented later this year.
MONARCH 3 is a global, double-blind, placebo-controlled Phase 3 clinical trial enrolling 493 postmenopausal women with HER2-negative advanced or metastatic breast cancer who have not received prior systemic therapy for their advanced disease. The study evaluates the efficacy and safety of Abemaciclib (150 mg twice daily) in combination with either Anastrozole (1 mg daily) or Letrozole (2.5 mg daily), compared to an aromatase inhibitor plus placebo.
The secondary endpoints include overall response rate, overall survival, and safety. Consistent with previous clinical evaluations of Abemaciclib, the most frequently reported adverse events include diarrhea, fatigue, nausea, and neutropenia.
Source: Eli Lilly and Company Investor Relations News.
Breast Cancer
- Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4